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Socioeconomic status and treatment outcomes for 
individuals with HIV on antiretroviral treatment in the UK: 
cross-sectional and longitudinal analyses
Lisa S Burch, Colette J Smith, Jane Anderson, Lorraine Sherr, Alison J Rodger, Rebecca O’Connell, Anna-Maria Geretti, Richard Gilson, Martin Fisher*, 
Jonathan Elford, Martin Jones, Simon Collins, Yusef Azad, Andrew N Phillips, Andrew Speakman, Margaret A Johnson, Fiona C Lampe, for the 
Antiretrovirals, Sexual Transmission Risk and Attitudes (ASTRA) Study Group
Summary
Background Few studies have assessed the eﬀ ect of socioeconomic status on HIV treatment outcomes in settings with 
universal access to health care. Here we aimed to investigate the association of socioeconomic factors with antiretroviral 
therapy (ART) non-adherence, virological non-suppression, and virological rebound, in HIV-positive people on ART in 
the UK.
Methods We used data from the Antiretrovirals, Sexual Transmission Risk and Attitudes (ASTRA) questionnaire study, 
which recruited participants aged 18 years or older with HIV from eight HIV outpatient clinics in the UK between 
Feb 1, 2011, and Dec 31, 2012. Participants self-completed a conﬁ dential questionnaire on sociodemographic, health, 
and lifestyle issues. In participants on ART, we assessed associations of ﬁ nancial hardship, employment, housing, and 
education with: self-reported ART non-adherence at the time of the questionnaire; virological non-suppression 
(viral load >50 copies per mL) at the time of questionnaire in those who started ART at least 6 months ago (cross-sectional 
analysis); and subsequent virological rebound (viral load >200 copies per mL) in those with initial viral load of 
50 copies per mL or lower (longitudinal analysis).
Findings Of the 3258 people who completed the questionnaire, 2771 (85%) reported being on ART at the time of the 
questionnaire, and 2704 with complete data were included. 873 (32%) of 2704 participants reported non-adherence to 
ART and 219 (9%) of 2405 had virological non-suppression in cross-sectional analysis. Each of the four measures of 
lower socioeconomic status was strongly associated with non-adherence to ART, and with virological non-suppression 
(prevalence ratios [PR] adjusted for gender/sexual orientation, age, and ethnic origin: greatest ﬁ nancial hardship vs 
none 2·4, 95% CI 1·6–3·4; non-employment 2·0, 1·5–2·6; unstable housing vs homeowner 3·0, 1·9–4·6; non-university 
education 1·6, 1·2–2·2). 139 (8%) of 1740 individuals had subsequent virological rebound (rate=3·6/100 person-years). 
Low socioeconomic status was predictive of longitudinal rebound risk (adjusted hazard ratio [HR] for greatest ﬁ nancial 
hardship vs none 2·3, 95% CI 1·4–3·9; non-employment 3·0, 2·1–4·2; unstable housing vs homeowner 3·3, 1·8–6·1; 
non-university education 1·6, 1·1–2·3).
Interpretation Socioeconomic disadvantage was strongly associated with poorer HIV treatment outcomes in this 
setting with universal health care. Adherence interventions and increased social support for those most at risk should 
be considered.
Funding National Institute for Health Research.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license.
Introduction
Substantial evidence exists of socioeconomic inequalities 
in the prognosis of chronic diseases. In Europe and the 
USA, socioeconomic factors such as poverty, low income, 
and low education level have been associated with poorer 
outcomes for several diseases, including cancer, and 
cardiovascular disease.1–3 Findings of other studies have 
suggested that  lower socioeconomic status (measured by 
education or income) is associated with poorer adherence 
to treatment, such as steroids for asthma4 and insulin for 
diabetes.5
HIV is a disease that disproportionately aﬀ ects those 
with socioeconomic disadvantage.6 In the USA, in 
people with HIV receiving antiretroviral therapy (ART), 
lower levels of socioeconomic status (as indicated by 
lower education level, unemployment, homelessness, 
or household poverty) are associated with having 
poorer virological and immunological outcomes.7–11 
HIV-positive populations in the UK and Europe also 
comprise distinct demographic groups, with substantial 
variation in social circumstances. As such, social 
inequalities may result in disparities in HIV health 
outcomes. However, in contrast to the USA, the UK has 
universal free access to health care, including HIV 
diagnosis, hospital consultations, and antiretroviral 
treatment, which should greatly lessen ﬁ nancial barriers 
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to accessing HIV treatment and care. Therefore, the 
associations between socioeconomic factors and HIV 
outcomes in the USA might not be generalisable to 
settings with free universal health care, which have 
been little studied.11 Findings of two large European 
studies, the Swiss HIV Cohort study12 and the Spanish 
CoRIS study,13 showed that lower education level was 
associated with increased odds of viral load being higher 
than 50 copies per mL at 12 months after ART initiation 
(unadjusted odds ratios of 1·3 and 1·9, respectively); 
however, the Danish HIV Cohort study14 noted no clear 
association. Additionally, in the Italian ICoNA cohort 
study15 in individuals who had been taking ART for at 
least 6 months, unemployment was associated with 
double the risk of virological failure compared with 
working full-time. No previous studies have looked at 
socioeconomic variations in virological outcomes in 
people treated for HIV in the UK. 
ART non-adherence is the major determinant of 
virological non-suppression and subsequent virological 
rebound,16 which in turn predicts poorer prognosis for 
people living with HIV.17 Thus, any eﬀ ect of socioeconomic 
status on virological outcome is likely to be mediated to a 
great extent through diﬀ erential patterns of adherence to 
HIV treatment. Findings of some European studies11,18–20 
have shown that lower socioeconomic status (measured 
by education, employment, and social support) is 
associated with ART non-adherence, but a minority of 
studies found no evidence.11,21
Here, with data from the Antiretrovirals, Sexual 
Transmission Risk and Attitudes (ASTRA) study, we aimed 
to investigate the association of socioeconomic factors with 
ART non-adherence, virological non-suppression, and 
virological rebound, in HIV-positive people on ART in 
the UK.
Methods
Study design and participants
ASTRA is a cross-sectional, questionnaire study of 
3258 HIV-diagnosed individuals in the UK recruited from 
eight HIV outpatient clinics between Feb 1, 2011, and 
Dec 31, 2012.22 Participants self-completed a conﬁ dential 
questionnaire on sociodemographic, health, and lifestyle 
issues. The most recent HIV viral load and CD4 count 
results available at the time of the questionnaire were 
recorded for all participants by study personnel. Six of the 
eight study clinics provided linkage to routine HIV clinical 
records (including serial viral load measurements) for 
consenting participants (2983 [92%]) using a pseudo-
anonymised study number. 
Demographic factors, socioeconomic factors, ART use 
and start date, and ART adherence were self-reported on 
the questionnaire. The demographic factors of interest 
were: gender/sexual orientation (men who have sex with 
men, heterosexual men, women), ethnic origin (white or 
non-white), and age (as a continuous variable). Men were 
classiﬁ ed as men who have sex with men if they 
self-identiﬁ ed as gay or bisexual, or reported sex with 
Research in context
Evidence before this study
We searched PubMed for studies assessing the associations 
between socioeconomic status and HIV treatment outcomes 
(search originally done in June, 2015, updated in February, 2016, 
and published in May, 2016). The papers included in the review 
were original research studies of any design and including 
secondary observational analyses of randomised controlled trial 
data in which the criteria for inclusion were: written in English; set 
in high-income countries; included more than 100 participants; 
recruitment not entirely before the modern highly active 
antiretroviral therapy era (ie, some recruitment after 2001); all 
participants prescribed antiretroviral therapy (ART); not solely 
reporting analyses adjusted for adherence. We used the following 
MeSH terms: “HIV” and any of “socioeconomic” or 
“socio-economic” or “antiretroviral” or “ART” with any “virologic” 
or “virological” or “immunologic” or “immunological” or “failure” 
of “rebound” or “suppression” or “viral load” or “CD4” or 
“education level” or “employment” or “housing” or “occupation” 
or “deprivation” or “poverty” or “income” or “insurance”. 
46 studies met the entry criteria, of which, ten (71%) of 14 noted 
an association between lower socioeconomic status and poorer 
virological response, four (67%) of six found an association 
between lower socioeconomic status and poorer immunological 
response, and 23 (66%) of 35 found an association between 
lower socioeconomic status and ART non-adherence. 
Most studies have been done in the USA (ie, without universal 
free access to health care) and have focused mainly on education 
rather than markers of current poverty and hardship. No previous 
studies have been done of socioeconomic status and ART 
response in people with HIV in the UK. 
Added value of this study
Our study provides evidence, from both cross-sectional and 
longitudinal analyses, that socioeconomic disadvantage 
(measured by ﬁ nancial hardship, non-employment, unstable 
housing status, and lower educational level) is an important 
determinant of HIV treatment outcomes in a setting with 
universal free access to health care and high rates of treatment 
success. Thus, our data suggest that the adverse eﬀ ect of 
socioeconomic disadvantage goes beyond the ability to access 
or pay for treatment and care.
Implications of all the evidence
Collection of information about socioeconomic factors in a 
routine clinical care setting is key to identifying individuals at 
greater risk of poorer virological response to ART. Adherence 
and social support for socioeconomically disadvantaged 
individuals should be regarded as an important component of 
clinical care.
For the ASTRA questionnaire 
see http://www.astra-study.org
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a man in the past 3 months. Four markers of 
socioeconomic status were considered: ability to aﬀ ord 
basic needs (ﬁ nancial hardship with four levels); 
employed (yes or no); housing status (homeowner; 
renting; unstable or other); and university education 
(yes or no). The following variables were additional 
markers of social circumstances: time living in the UK 
(UK born, >5 years, ≤5 years), English reading ability 
(UK born, ﬂ uent, not ﬂ uent), supportive network 
(most, medium, least), current stable partner (yes or no), 
and children (yes or no).
Financial hardship was derived from the question 
“Do you have enough money to cover your basic needs? 
(Eg, food and heating)” for which responses were: “Yes, 
all of the time”; “Yes, most of the time”; “Yes, some of 
the time”; “No”. “Employed” included those who 
reported either full-time or part-time employment 
(or self-employment). For housing status, “rented” 
included those who rented privately or from the council 
or housing association; “unstable or other” included 
those living in a hostel, shelter, squat, other temporary 
accommodation; those staying with partner, family, or 
friends; and those who were homeless. “Supportive 
network” aimed to measure supportive relationships 
based on a modiﬁ cation of the Duke UNC Functional 
Social Support Questionnaire.23 Participants scored from 
1: “much less than I would like” to 5: “as much as I 
would like”, on ﬁ ve items: whether they have people who 
care what happens to them; they receive love and 
aﬀ ection; they get chances to talk to someone they trust; 
they get invited to do things; they get help when sick. 
Scores were classiﬁ ed as follows: 5–12 “least support”; 
13–24 “medium support”; 25 “most support.”
Ethical approval was obtained via the North West London 
REC 2 research ethics committee (ref 10/H0720/70).
Cross-sectional analysis
We assessed the associations of socioeconomic and 
social circumstance factors with ART non-adherence 
and virological non-suppression at the time of the 
questionnaire. For the non-adherence analysis, inclusion 
criteria were: on ART at the time of the questionnaire, a 
non-missing value for age, and a non-missing value 
for at least one of two ART-adherence questions. ART 
non-adherence was deﬁ ned as either an aﬃ  rmative 
response to the question: “In the past 3 months, have you 
ever missed your HIV treatment for 2 or more days at 
a time?” or reporting one or more missed doses in 
response to the question: “In the last 2 weeks, how many 
doses of HIV treatment have you missed?”
For the virological non-suppression analysis, in 
addition to the criteria for the non-adherence analysis, 
individuals were required to: have a non-missing value 
for clinic-recorded viral load (the latest value at the time 
of questionnaire, using either the study recorded value or 
available linked clinic data); have a non-missing value for 
date of ART initiation; have started ART at least 6 months 
before the viral load measurement being used for 
analysis. Virological non-suppression was deﬁ ned as 
viral load more than 50 copies per mL.
Cross-sectional analysis*; 
participants included in 
non-adherence analysis 
(N=2704)† 
Longitudinal analysis‡; 
participants included in viral 
load rebound analysis 
(N=1740)†
Gender/sexual orientation
Men who have sex with men 1867 (69%) 1267 (73%)
Heterosexual men 321 (12%) 171 (10%)
Women 516 (19%) 302 (17%)
Risk group
Sex between men 1748 (65%) 1195 (69%)
Heterosexual sex 536 (20%) 314 (18%)
Injecting drug use 46 (2%) 25 (1%)
Other 353 (13%) 197 (11%)
Missing 21 (1%) 9 (1%)
Ethnic origin 
White 1875 (69%) 1259 (72%)
Black African 507 (19%) 281 (16%)
Black other 89 (3%) 52 (3%)
Other 184 (7%) 113 (6%)
Missing 49 (2%) 35 (2%)
Age
Median (IQR) 46 (40–52) 46 (41–52)
Aﬀ ord basic needs (ﬁ nancial hardship)§
Always 1170 (43%) 814 (47%)
Mostly 701 (26%) 454 (26%)
Sometimes 464 (17%) 265 (15%)
No 326 (12%) 176 (10%)
Missing 43 (2%) 31 (2%)
Employment
Employed 1479 (55%) 985 (57%)
Unemployed 483 (18%) 286 (16%)
Sick or disabled 375 (14%) 224 (13%)
Retired 180 (7%) 129 (7%)
Other 127 (5%) 79 (5%)
Missing 49 (2%) 37 (2%)
Housing
Homeowner 914 (35%) 658 (38%)
Renting from council 840 (31%) 522 (30%)
Renting privately 609 (23%) 393 (23%)
Temporary accommodation or homeless 70 (3%) 35 (2%)
Staying with family 191 (7%) 97 (6%)
Other 10 (<1%) 6 (<1%)
Missing 40 (1%) 29 (2%)
Education (highest level)
University degree or higher 1094 (40%) 759 (44%)
A-level or equivalent 536 (20%) 338 (19%)
O-levels or equivalent 601 (22%) 364 (21%)
Other 108 (4%) 70 (4%)
None 302 (11%) 169 (10%)
Missing 63 (2%) 40 (2%)
(Table 1 continues on the next page)
Articles
e29 www.thelancet.com/public-health   Vol 1   November 2016
We summarised the prevalence of ART non-adherence 
and virological non-suppression according to demo-
graphic, socioeconomic, and social circumstance factors; 
groups were compared with the χ² test or 
Cochran-Armitage test for trend for ordered categorical 
variables. Unadjusted and adjusted prevalence ratios for 
associations of socioeconomic and social circumstance 
factors with ART non-adherence and virological 
non-suppression, were generated using modiﬁ ed 
Poisson regression models.24 For multivariable models, 
each socioeconomic and social circumstance factor was 
considered in a separate model because of high 
co-linearity; associations were adjusted for demographic 
factors (gender/sexual orientation, ethnic origin, and 
age). We also assessed the association between ART 
non-adherence and virological non-suppression with 
modiﬁ ed Poisson regression, adjusted for demographic 
factors.
We did a subgroup analysis in white men who have sex 
with men to reduce confounding by demographic, 
ethnic, and cultural factors. We also did a sensitivity 
analysis in which a viral load of more than 
200 copies per mL was deﬁ ned as non-suppression, 
because low level viraemia might not be indicative of true 
virological failure.
Longitudinal analysis
We did a longitudinal analysis to assess the associations 
of socioeconomic and social circumstance factors with 
risk of virological rebound. We included consenting 
ASTRA participants from the six centres for which linked 
clinic data were available. Baseline was deﬁ ned as the 
date of questionnaire. Inclusion criteria were: on ART 
with viral load of 50 copies per mL or lower at baseline 
(latest value at the time of the questionnaire); started 
ART at least 6 months before the baseline viral load 
measurement; non-missing value for age; non-missing 
value for at least one ART-adherence question; and at 
least one viral load measurement subsequent to baseline. 
Individuals were followed up from baseline until 
virological rebound (deﬁ ned as the ﬁ rst viral load 
>200 copies per mL) or the last available viral load (latest 
Oct 9, 2015). Follow up was not censored at ART 
interruption.
We assessed the unadjusted and adjusted associations 
of socioeconomic and social circumstance factors with 
subsequent virological rebound with Kaplan-Meier plots 
and Cox proportional hazards regression models. 
We used separate multivariate models for every 
socioeconomic and social circumstance factor, adjusted 
for demographic factors (gender/sexual orientation, 
ethnic origin, and age). Additionally, we assessed the 
association between ART non-adherence and viral load 
rebound with Cox proportional hazards regression, 
adjusted for demographic factors.
We did a subgroup analysis restricted to white men 
who have sex with men in order to reduce confounding. 
Two sensitivity analyses were done: virological rebound 
was deﬁ ned as two consecutive viral load measurements 
more than 200 copies per mL to investigate an endpoint 
Cross-sectional analysis*; 
participants included in 
non-adherence analysis 
(N=2704)† 
Longitudinal analysis‡; 
participants included in viral 
load rebound analysis 
(N=1740)†
(Continued from previous page)
Time in UK
Born in UK 1511 (56%) 983 (56%)
>5 years 991 (37%) 635 (36%)
≤5 years 116 (4%) 68 (4%)
Missing 86 (3%) 54 (3%)
English reading ability
Born in UK 1511 (56%) 983 (56%)
Fluent 912 (34%) 595 (34%)
Not ﬂ uent 208 (8%) 114 (7%)
Missing 73 (3%) 48 (3%)
Supportive network
Most support 878 (32%) 562 (32%)
Medium support 1414 (52%) 930 (53%)
Least support 377 (14%) 227 (13%)
Missing 35 (1%) 21 (1%)
Children
Yes 733 (27%) 426 (24%)
No 1954 (72%) 1305 (75%)
Missing 17 (1%) 9 (1%)
Partner
Yes 1530 (57%) 997 (57%)
No 1158 (43%) 731 (42%)
Missing 16 (1%) 12 (1%)
Time since HIV diagnosis
<2 years 180 (7%) 64 (4%)
2–5 years 361 (13%) 222 (13%)
5–15 years 1345 (50%) 926 (53%)
>15 years 755 (28%) 528 (30%)
Missing 63 (2%) 0 
Number of times taking ART per day
1 2159 (80%) 1419 (81%)
≥2 513 (19%) 309 (18%)
Missing 32 (1%) 21 (1%)
≥2 consecutive missed days of ART in the past 3 months
No or unknown 2236 (83%) 1461 (84%)
Yes 464 (17%) 277 (16%)
Missing 4 (<1%) 2 (<1%)
≥1 missed dose in the past 2 weeks
No or unknown 2022 (75%) 1289 (74%)
Yes 676 (25%) 447 (26%)
Missing 6 (<1%) 4 (<1%)
Non-adherent to ART¶
No or unknown 1831 (68%) 1174 (67%)
Yes 873 (32%) 566 (33%)
(Table 1 continues on the next page)
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of sustained viral rebound; and those who were lost to 
follow-up (eligible for the longitudinal analysis but date 
of last measurement was more than 18 months before 
the clinic administrative censoring date) were regarded 
as having experienced virological rebound 6 months after 
the date of the last available viral load measurement, 
because lack of retention in care may be associated with 
poorer prognosis.
Complete-case analyses were done throughout because 
the proportion of participants with missing data did not 
exceed 4% for any variable used in the analysis. 
We used SAS (version 9.3) for all statistical analyses.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had ﬁ nal responsibility for 
the decision to submit for publication. FCL, CJS, and AS 
also had full access to the data.
Results
Between Feb 1, 2011, and Dec 31, 2012, 5112 HIV-diagnosed 
men and women were invited to participate in the 
ASTRA study, of whom 4200 (82%) consented to take 
part. 3258 individuals completed the questionnaire 
(response rate 64% of the 5112 individuals approached). 
Of the 3258 people (69% men who have sex with men, 
11% heterosexual men, and 20% women) who completed 
the questionnaire, 2771 (85%) reported being on ART at 
the time of the questionnaire. Of the remaining 
487 (15%) people not on ART, 366 (11%) were ART-naive 
individuals, 65 (2%) had stopped ART, and 56 (2%) had 
missing ART information. Of the 2771 participants 
currently on ART, 58 (2%) had missing age, and 
nine (<1%) had not responded to either adherence 
question. This resulted in 2704 individuals being 
included (1867 men who have sex with men, 
321 heterosexual men, and 516 women; table 1).
Of the 2704 participants on ART, 873 (32%, 95% CI 
31–34) reported ART non-adherence. Individuals with 
lower socioeconomic status by any measure (ie, 
increased ﬁ nancial hardship, non-employment, rented 
or unstable housing status, and non-university 
education) were more likely to report ART non-adherence 
(ﬁ gure 1 and table 2). In terms of social circumstance 
factors, the prevalence of ART non-adherence was 
higher in individuals who had lived in the UK for more 
than 5 years but were not born in the UK, those who had 
non-ﬂ uent English reading ability, those who reported 
lower supportive network, those who had children, and 
those who did not have a current partner (ﬁ gure 1 and 
table 2). After adjustment for demographic factors 
(gender/sexual orientation, ethnic origin, and age), 
all measures of poor socioeconomic status remained 
associated with an increased prevalence of ART 
non-adherence (table 2). Associations of non-adherence 
with non-ﬂ uent English, lower supportive network, 
having children, and no current partner also remained 
after adjustment for demographic factors, while the 
association with time in the UK was largely accounted 
for by the demographic factors (table 2). In a model 
that included only demographic factors, non-white 
ethnic origin (prevalence ratio [PR] 1·33 vs white, 
95% CI 1·14–1·54) and younger age (PR 0·89 per 
10 years older, 95% CI 0·84–0·95) were independently 
associated with non-adherence. However, we noted no 
independent association with gender/sexual orientation 
(PR 0·92 for heterosexual men and 0·99 for women vs 
men who have sex with men).
The virological non-suppression analysis included 
2405 (89%) participants who had a recorded viral load and 
date of ﬁ rst ART initiation, and started ART more than 
6 months before the viral load measurement. Of these, 
219 (9%, 95% CI 8–10) had virological non-suppression 
(viral load >50 copies per mL; 79 [36%] with 
>500 copies per mL, 68 [31%] >1000 copies per mL, and 
32 [15%] >10 000 copies per mL). As reported for ART 
non-adherence, for each of the four indicators of 
socioeconomic status, socioeconomic disadvantage was 
strongly associated with virological non-suppression 
(ﬁ gure 1 and table 2). Additionally, individuals with 
non-ﬂ uent English reading ability and those who had 
children had an increased prevalence of virological 
non-suppression. There were weaker associations with 
non-suppression for individuals who were non-UK born 
and lived in the UK for more than 5 years, those who had 
lower supportive network, and those who had no current 
partner (ﬁ gure 1 and table 2). Although socioeconomic 
Cross-sectional analysis*; 
participants included in 
non-adherence analysis 
(N=2704)† 
Longitudinal analysis‡; 
participants included in viral 
load rebound analysis 
(N=1740)†
(Continued from previous page)
Time on ART (years)||
Median (IQR) 6·9 (2·8–12·4) 7·7 (3·7–12·9)
CD4 count (cells per mm³)||
Median (IQR) 546 (393–732) 590 (442–780)
Viral load at the time of the questionnaire
≤50 copies per mL 2347 (87%) 1740 (100%)
>50 copies per mL 341 (13%)** 0
Missing 16 (1%) 0
Data are n (%) unless stated otherwise. ART=antiretroviral therapy. *All participants who self-reported being on ART at 
the time of the questionnaire and had recorded age and non-adherence information. Of these, 2405 participants had a 
recorded viral load and date of ART initiation, and additionally started ART >6 months before the viral load 
measurement and were included in viral load non-suppression analysis. †Some column percentages do not add to 1 
because of rounding. ‡All participants had linked clinical data, recorded age and non-adherence information, were on 
ART, had viral load ≤50 copies per mL at the time of the questionnaire, started ART >6 months before the baseline viral 
load measurement, and had ≥1 subsequent viral load measurement. §Deﬁ ned as having money for basic needs. 
¶Self-reported ≥2 consecutive missed days of ART in the past 3 months or ≥1 missed dose in the past 2 weeks. 
||Cross-sectional N=99 and longitudinal N=0 with missing time on ART, cross-sectional N=17 and longitudinal N=2 with 
missing CD4 count. **Among 2405 participants that had additionally started ART >6 months before completion of the 
questionnaire and were included in viral load non-suppression analysis, 219 (9%) had viral load >50 copies per mL.
Table 1: Participants’ characteristics 
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disadvantage was strongly associated with non-
suppression, the proportion of individuals with a viral 
load of more than 50 copies per mL was no more than 
17% across all subgroups considered.
Table 2 also shows the adjusted associations of 
socioeconomic factors with virological non-suppression. 
The markers of lower socioeconomic status (ﬁ nancial 
hardship, non-employment, non-homeownership, and 
non-university education) all remained strongly associated 
with virological non-suppression after adjustment for 
demographic factors. We noted a marked trend between 
increasing prevalence of virological non-suppression and 
both increasing ﬁ nancial hardship and increasing housing 
instability. In terms of the additional social circumstance 
factors, having a lower supportive network and not having 
a current partner were associated with increased 
prevalence of virological non-suppression in the model 
adjusted for demographic factors. Living in the UK for 
less than 5 years was associated with lower prevalence of 
virological non-suppression compared with individuals 
born in the UK. The associations with low English ﬂ uency 
and having children were substantially attenuated. 
Because 76% of women had children compared with 7% 
of men who have sex with men, in unadjusted analyses 
the association between having children and higher 
prevalence of virological non-suppression could reﬂ ect an 
association with gender/sexual orientation.
In a model that included only demographic 
factors, younger age (PR 0·77 per 10 years older, 
95% CI 0·66–0·88) was independently associated with 
virological non-suppression, and there was some 
evidence of associations of gender/sexual orientation 
(PR 1·45 for heterosexual men vs men who have sex with 
men, 95% CI 0·96–2·19 and 0·99 for women vs men 
who have sex with men, 95% CI 0·66–1·47) and ethnic 
origin (1·41 non-white vs white, 0·98–2·01) with 
non-suppression. Self-reported ART non-adherence 
was associated with 2·4 times higher prevalence of 
virological non-suppression (PR 2·37, 95% CI 1·84–3·07; 
p<0·0001), adjusted for demographic factors only. 
Of 2405 participants included in the cross-sectional 
viral load analysis, 1740 (72%) had linked clinical data 
Figure 1: Prevalence of (A) antiretroviral therapy (ART) non-adherence and (B) virological non-suppression (viral load >50 copies per mL), by socioeconomic and demographic factors 
(A) Data taken from a cross-sectional analysis in 2704 respondents who were on ART at the time of the questionnaire. Self-reported ≥2 consecutive missed days of ART in the past 3 months or 
≥1 missed dose in the last 2 weeks. (B) Data taken from a cross-sectional analysis in 2405 respondents who were on ART and had started ART >6 months before the viral load measurement. MSM=men 
who have sex with men. *Calculated with Cochran-Armitage test for trend. †Calculated with χ² test.
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available and met the inclusion criteria for the 
longitudinal analysis (table 1). These individuals were 
followed up for 3818 person-years with a median of 
2·4 years (IQR 2·0–2·7) of follow-up and a median of six 
(IQR 5–8) viral load measurements per person. During 
this period, eight (<1%) individuals died. During 
follow-up, 139 (8%) people had virological rebound, 
corresponding to a rate of 3·6 per 100 person-years 
(95% CI 3·0–4·2). By 12 and 24 months of follow-up, the 
Kaplan-Meier estimates of virological rebound were 
3·9% (95% CI 3·0–4·8) and 7·0% (5·7–8·2), respectively.
In unadjusted Cox regression analysis, increased 
ﬁ nancial hardship, non-employment, and rented or 
unstable housing status were strongly predictive of 
increased risk of virological rebound (ﬁ gure 2 and table 3). 
We noted a more modest association between 
non-university education and increased rebound risk 
(ﬁ gure 2D and table 3). Additionally, having children 
and not having a partner were associated with a higher 
risk of rebound; data also suggested an association with 
lower supportive network. The pattern of associations 
remained, with some attenuation for some factors, after 
ART non-adherence‡ Viral load non-suppression§
Unadjusted Adjusted for demographic factors¶ Unadjusted Adjusted for demographic factors¶
PR (95% CI) p value|| aPR (95% CI) p value|| PR (95% CI) p value|| aPR (95% CI) p value||
Enough money for basic needs? (ﬁ nancial hardship)
Always 1 <0·0001** 1 <0·0001** 1 <0·0001** 1 <0·0001
Mostly 1·44 (1·24–1·66) 1·42 (1·22–1·64) 1·63 (1·15–2·30) 1·56 (1·11–2·21)
Sometimes 1·88 (1·62–2·17) 1·81 (1·56–2·11) 2·06 (1·44–2·95) 1·84 (1·26–2·68)
No 1·82 (1·55–2·14) 1·74 (1·46–2·06) 2·68 (1·87–3·86) 2·35 (1·60–3·43)
Employed
Yes 1 0·0002 1 <0·0001 1 <0·0001 1 <0·0001
No 1·24 (1·11–1·38) 1·29 (1·15–1·45) 1·85 (1·42–2·41) 1·96 (1·49–2·58)
Housing status
Homeowner 1 <0·0001** 1 <·0001** 1 <0·0001** 1 <0·0001 
Renting 1·44 (1·27–1·65) 1·34 (1·17–1·54) 2·39 (1·69–3·39) 2·09 (1·46–2·98)
Unstable 1·76 (1·47–2·10) 1·58 (1·31–1·91) 3·70 (2·42–5·67) 2·96 (1·90–4·59)
University education
Yes 1 0·0041 1 0·0028 1 0·0004 1 0·0003
No 1·18 (1·05–1·33) 1·19 (1·06–1·34) 1·63 (1·23–2·16) 1·63 (1·23–2·16)
Time in the UK
Born in the UK 1 0·0010 1 0·086 1 0·083 1 0·044
>5 years 1·24 (1·11–1·39) 1·07 (0·93–1·24) 1·30 (1·00–1·69) 0·89 (0·65–1·22)
≤5 years 1·00 (0·75–1·34) 0·80 (0·59–1·08) 0·75 (0·34–1·67) 0·45 (0·20–1·02)
English reading ability
Born in UK 1 <0·0001 1 0·0048 1 0·036 1 0·066
Fluent 1·13 (1·00–1·28) 1·00 (0·87–1·16) 1·09 (0·82–1·45) 0·77 (0·55–1·07)
Not ﬂ uent 1·59 (1·35–1·88) 1·37 (1·12–1·67) 1·89 (1·29–2·78) 1·19 (0·74–1·93)
Supportive network
Most 1 <0·0001** 1 <0·0001** 1 0·071** 1 0·031
Medium 1·39 (1·22–1·60) 1·40 (1·22–1·60) 1·07 (0·80–1·44) 1·12 (0·83–1·51)
Least 1·63 (1·38–1·93) 1·65 (1·39–1·95) 1·49 (1·03–2·15) 1·59 (1·10–2·30)
Children
Yes 1 0·0030 1 0·022 1 0·0053 1 0·29
No 0·83 (0·74–0·94) 0·83 (0·70–0·97) 0·67 (0·51–0·87) 0·80 (0·53–1·21)
Partner
Yes 1 0·0037 1 0·0014 1 0·094 1 0·026
No 1·18 (1·06–1·31) 1·20 (1·07–1·34) 1·25 (0·97–1·61) 1·35 (1·04–1·75)
Each socioeconomic factor considered in a separate model for all results; individuals with missing values for explanatory variables were excluded.ART=antiretroviral therapy. 
PR=prevalence ratio. aPR=adjusted prevalence ratio. *Self-reported ≥2 consecutive missed days of ART in the past 3 months or ≥1 missed dose in the last 2 weeks. †Viral load 
>50 copies per mL at the time of the questionnaire. ‡Cross-sectional analysis in 2704 respondents who were on ART at the time of the questionnaire. §Cross-sectional 
analysis among 2405 respondents who were on ART and had started ART >6 months before the viral load measurement. ¶Gender/sexual orientation–ethnic origin–and age. 
||Calculated with χ² test. **Test for trend. 
Table 2: Associations of socioeconomic factors with antiretroviral non-adherence*and virological non-suppression† 
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adjustment for demographic factors (table 3). In a model 
for viral load rebound containing only the demographic 
factors, there were independent associations of gender/
sexual orientation (HR 2·00 for heterosexual men vs 
men who have sex with men, 95% CI 1·15–3·47; HR 1·45 
for women vs men who have sex with men, 
95% CI 0·87–2·41) and younger age (PR 0·74 per 
10 years older, 95% CI 0·61–0·90) with virological 
rebound, but no evidence of association with ethnic 
origin (HR 1·32, 95% CI 0·83–2·09 for non-white vs 
white). Individuals who self-reported ART non-
adherence at baseline had more than three times the 
rate of virological rebound compared with individuals 
who did not (HR 3·11, 95% CI 2·20–4·38; p<0·0001, 
adjusted for demographic factors only).
Among the subgroup of white men who have sex with 
men, the markers of lower socioeconomic status remained 
strongly associated with increased prevalence of ART 
non-adherence and virological non-suppression, and 
increased rates of virological rebound (appendix pp 1, 2). 
Results of all sensitivity analyses for cross-sectional and 
longitudinal analyses were broadly consistent with those 
of the main analyses (appendix pp 3, 4).
Discussion
This is the ﬁ rst study to assess the eﬀ ect of socioeconomic 
status on virological outcomes in people receiving 
treatment for HIV in the UK. In this setting of universal 
access to health care and high levels of treatment success, 
all four markers of lower socioeconomic status 
considered (ﬁ nancial hardship, non-employment, rented 
or unstable housing status, and non-university education) 
were strongly associated with ART non-adherence and 
virological non-suppression on ART. Furthermore, each 
of the four markers of lower socioeconomic status was 
predictive of subsequent virological rebound in people 
Figure 2: Kaplan-Meier plots of time until virological rebound (viral load >200 copies per mL) according to (A) ability to aﬀ ord basic needs (ﬁ nancial hardship), (B) employment status, 
(C) housing status, and (D) university education
Longitudinal analysis in 1740 respondents on ART with viral load <50 copies per mL at the time of the questionnaire. Individuals with missing values were excluded. Numbers provided indicate the 
number of individuals at risk.
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with viral suppression at baseline. These results provide 
evidence of the importance of current socioeconomic 
disadvantage in determining virological outcomes of 
ART. The adverse implications of poorer socioeconomic 
status clearly go beyond inability to pay for treatment and 
health care, and operate strongly even in people engaged 
with clinical care.
In previous European studies11–14 of socioeconomic status 
and ART outcomes in which education level was used as 
the sole indicator of socioeconomic status, lower education 
level was associated with virological non-suppression 
in two of three studies. Two additional European 
studies considered employment status and noted that 
unemployment was associated with twice the adjusted risk 
of virological failure15 and that viral load of more than 
50 copies per mL was associated with twice the unadjusted 
odds of developing inability to work among those able to 
work when starting ART.25 In terms of mortality risk, in 
a French study of individuals starting ART, social 
vulnerability (combining education, employment, and 
housing status) was associated with 20% increased 
mortality risk after adjustment for behavioural and 
biomedical factors.26 The results of this present analysis 
add to existing ﬁ ndings  showing strong associations 
between current markers of poverty and hardship and viral 
load response to ART in people with HIV in the UK.
Adherence to treatment is the strongest determinant of 
virological response to ART.16 The strong association 
between socioeconomic factors and ART non-adherence, 
and between non-adherence and virological outcomes, 
suggest that associations between low socioeconomic 
status and virological non-suppression are probably 
mediated mainly through ART non-adherence. It is 
important to appreciate the apparent substantial eﬀ ect of 
socioeconomic factors on non-adherence, even in the 
current era of simpler and more tolerable drugs, with most 
participants on once a day regimens. There are a number 
of reasons why people with greater levels of social or 
ﬁ nancial disadvantage might have greater diﬃ  culties 
maintaining treatment adherence, including competing 
responsibilities and stress, unsettled living circumstances, 
food insecurity (particularly when ART regimen requires 
food),27 increased prevalence of mental health problems,18 
stigma and low self-esteem, or less knowledge about the 
importance of adherence.28 It is also conceivable that part 
of the eﬀ ect of socioeconomic status on virological 
outcomes is independent of non-adherence, for example 
related to factors such as late diagnosis,29 low CD4 count or 
AIDS at ART initiation,30 diﬀ erences in experiences or 
quality of health care, and pharmacokinetics through 
absence of suﬃ  cient food.31 
The results of this study have practical implications to 
guide the identiﬁ cation of individuals on ART who are at 
higher risk of ART non-adherence and poorer treatment 
outcomes. Individuals with diﬃ  cult socioeconomic 
circumstances might beneﬁ t from speciﬁ c support with 
ART adherence such as prescription of less complex 
regimens,32 or interventions such as peer support.33 
Moreover, the results show  that the success of treatment 
cannot be separated from the social context in which it 
occurs. They emphasise the importance of a holistic 
approach to HIV care, with awareness that diﬃ  culties in 
individuals’ circumstances aﬀ ect treatment success, and 
good links to social care services that can support 
individuals in addressing diﬃ  culties with ﬁ nance and 
beneﬁ ts, housing, and employment issues. However, our 
ﬁ ndings also raise the agenda of socioeconomic 
inequalities in health in a wider context, adding to existing 
evidence of the adverse eﬀ ect of poverty and social 
N Rate per 
100 person-
years  
Unadjusted Adjusted for demographic 
factors†
HR (95% CI) p value‡ aHR (95% CI) p value§
Enough money for basic needs? (ﬁ nancial hardship)
Always 814 2·49 1 <0·0001§ 1 0·0005§
Mostly 454 3·64 1·47 (0·95–2·27) 1·34 (0·86–2·09)
Sometimes 265 5·60 2·25 (1·43–3·55) 1·86 (1·15–3·01)
No 176 6·95 2·78 (1·71–4·53) 2·34 (1·39–3·92)
Employed
Yes 985 2·26 1 <0·0001 1 <0·0001
No 718 5·78 2·56 (1·81–3·62) 2·95 (2·05–4·25)
Housing status
Homeowner 658 1·70 1 <0·0001§ 1 <0·0001§
Renting 915 4·76 2·80 (1·81–4·32) 2·40 (1·52–3·79)
Unstable/other 138 6·95 4·11 (2·27–7·42) 3·30 (1·77–6·13)
University education
Yes 759 2·79 1 0·021 1 0·014
No 941 4·24 1·52 (1·07–2·17) 1·57 (1·10–2·26)
Time in the UK
Born in UK 983 3·09 1 0·11 1 0·51
In UK >5 years 635 4·47 1·44 (1·02–2·04) 0·95 (0·61–1·48)
In UK ≤5 years 68 2·96 0·95 (0·35–2·59) 0·54 (0·19–1·54)
English reading ability
Born in UK 983 3·09 1 0·14 1 0·81
Fluent 595 4·35 1·40 (0·98–2·00) 0·92 (0·59–1·42)
Not ﬂ uent 114 4·43 1·43 (0·74–2·78) 0·78 (0·37–1·66)
Supportive network
Most support 562 3·07 1 0·070§ 1 0·044§
Medium 
support
930 3·68 1·20 (0·81–1·77) 1·20 (0·81–1·87)
Least support 227 5·04 1·63 (0·98–2·72) 1·76 (1·05–2·94)
Children
Yes 426 6·03 1 <0·0001 1 0·014
No 1305 2·91 0·49 (0·34–0·68) 0·53 (0·32–0·88)
Partner
Yes 997 2·96 1 0·0081 1 0·0021
No 731 4·65 1·57 (1·12–2·19) 1·71 (1·21–2·40)
Every socioeconomic factor was considered in a separate model for all results; individuals with missing values for 
explanatory variables were excluded. HR=hazard ratio. aHR=adjusted hazard ratio. *Longitudinal analysis in 
1740 respondents on ART with viral load <50 copies per mL at the time of the questionnaire. †Gender/sexual 
orientation, ethnic origin, and age. ‡Calculated with χ² test. §Test for trend. 
Table 3: Associations of socioeconomic factors with virological rebound (viral load >200 copies per mL)*
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disadvantage on health outcomes.34 Socioeconomic factors 
are often not incorporated in clinical research studies of 
HIV; however, our results show that such factors are likely 
to be profound determinants of HIV outcomes. As such, 
there is a need for systematic collection of socioeconomic 
factors in HIV clinical care and research.
There are some limitations to this study. The ASTRA 
questionnaire study response rate was 64%: non-
responders might diﬀ er from responders with regard to 
socioeconomic factors and association with virological 
outcomes. Our sample had a lower proportion of black 
African individuals, a lower proportion of individuals 
who acquired HIV through heterosexual sex, and a 
greater proportion of men who have sex with men than 
among people living with HIV in the UK generally.35 We 
did not account for whether participants were on ﬁ rst-line 
or subsequent ART regimens, and the speciﬁ c regimen 
used. Our measures of socioeconomic status and 
adherence to ART were collected at one timepoint only 
and by self-report. We did not include 65 individuals who 
had previously been on ART but were not on ART at the 
time of the questionnaire; when this group were 
included in cross-sectional analyses as non-adherent, the 
prevalence of non-adherence and non-suppression was 
slightly higher than seen in the main analysis (34% vs 32%, 
and 11% vs 9% respectively), but socioeconomic 
associations were unchanged (data not shown). In the 
cross-sectional analysis, only association can be studied; it 
is not possible to rule out the presence of reverse causality 
for some factors. However, all ﬁ ndings are reinforced in 
the longitudinal analysis, which is unlikely to suﬀ er from 
this bias. Longitudinal time-to-rebound analyses are 
potentially subject to bias if frequency of viral load 
monitoring diﬀ ers according to explanatory variables; 
however, the median number of viral load measurements 
during follow-up was very similar across socioeconomic 
subgroups (data not shown).
In summary, even in a European setting with free 
access to HIV treatment and overall high rates 
of treatment success, socioeconomic disadvantage 
substantially aﬀ ects HIV treatment outcomes. Emphasis 
should be placed on supporting adherence of people 
in these higher risk groups. Socioeconomic factors 
should be taken into account when designing clinical 
management strategies including linkage to the relevant 
social care agencies. Further research is needed on 
speciﬁ c interventions that reduce socioeconomic 
inequalities in HIV-outcomes.
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